Novo Nordisk : NVO

All Novo Nordisk Articles

151 Articles

David Beren | Feb 25, 2026 at 7:08 AM EST

Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low

After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO | NVO Price Prediction) has dropped 22% in the…

David Beren | Feb 16, 2026 at 2:00 PM EST

Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery

Editor’s note: A prior version of this article stated Eli Lilly and Nvidia had funded a supercomputer, when the commitment…

John Seetoo | Feb 11, 2026 at 7:15 AM EST

GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching

One of the biggest trends in the fight against obesity has been the explosion in popularity of GLP-1 medications. Created…

Austin Smith | Feb 9, 2026 at 11:59 AM EST

HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. The telehealth company pulled…

Douglas A. McIntyre | Feb 9, 2026 at 10:39 AM EST

Hims & Hers Falls Apart, Again

Hims & Hers Health (NASDAQ: HIMS) has had among the worst runs of any public company over the last year.…

Rich Duprey | Feb 4, 2026 at 2:39 PM EST

Eli Lilly Is Dominating the GLP-1 Wars as Novo Nordisk Sales Tank

The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly (NYSE:LLY | LLY Price Prediction) and Novo Nordisk (NYSE:NVO)…

Austin Smith | Jan 23, 2026 at 10:36 AM EST

VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion

The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution.…

Joel South | Jan 21, 2026 at 8:20 AM EST

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)

Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. With promising new treatments in the pipeline,…

Ian Cooper | Dec 24, 2025 at 9:47 AM EST

Stock Market Live December 24, 2025: S&P 500 (SPY) at Record Highs

With the holidays upon us, markets aren’t moving much. Instead, many are taking time off to enjoy the holidays and…

Rich Duprey | Dec 23, 2025 at 1:23 PM EST

Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?

Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk‘s (NYSE:NVO | NVO Price Prediction) Wegovy weight-loss pill, the first…

Ian Cooper | Dec 23, 2025 at 8:58 AM EST

Premarket Movers: Albemarle Gaining Momentum on Lithium Boom

Albemarle (NYSE: ALB | ALB Price Prediction) had an incredible year. Since bottoming out at around $50 in April, the…

Douglas A. McIntyre | Nov 14, 2025 at 4:13 PM EST

Retail Investors Really Don’t Like Novo Nordisk (NVO) Stock

Shares of Novo Nordisk A/S (NYSE: NVO | NVO Price Prediction) dropped 1.9%today, closing at $48.25, just a whisker above…

Omor Ibne Ehsan | Nov 11, 2025 at 10:07 AM EST

3 Buy-And-Forget Dividend Stocks With Snowballing Payouts

If the headline yield today is not something you’re concerned with, and you pay more attention to how fast a…

Trey Thoelcke | Nov 5, 2025 at 8:45 AM EST

Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More

In the past week or so, a biotech and an energy infrastructure giant saw some huge insider buying. These were…

Rich Duprey | Nov 3, 2025 at 10:13 AM EST

Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that…

1 2 3 4 … 11

Novo Nordisk : NVO

All Novo Nordisk Articles

Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low

Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery

GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching

HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Hims & Hers Falls Apart, Again

Eli Lilly Is Dominating the GLP-1 Wars as Novo Nordisk Sales Tank

VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)

Stock Market Live December 24, 2025: S&P 500 (SPY) at Record Highs

Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?

Premarket Movers: Albemarle Gaining Momentum on Lithium Boom

Retail Investors Really Don’t Like Novo Nordisk (NVO) Stock

3 Buy-And-Forget Dividend Stocks With Snowballing Payouts

Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More

Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

Novo Nordisk : NVO

All Novo Nordisk Articles

Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low

Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery

GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching

HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Hims & Hers Falls Apart, Again

Eli Lilly Is Dominating the GLP-1 Wars as Novo Nordisk Sales Tank

VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)

Stock Market Live December 24, 2025: S&P 500 (SPY) at Record Highs

Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?

Premarket Movers: Albemarle Gaining Momentum on Lithium Boom

Retail Investors Really Don’t Like Novo Nordisk (NVO) Stock

3 Buy-And-Forget Dividend Stocks With Snowballing Payouts

Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More

Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

China’s Semiconductor Equipment Companies Gain Share Despite U.S. Sanctions

Featured Reads

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026